Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - a retrospective analysis

被引：32

作者：

Hove, Karin D. ^{[1
]}

Foerch, Kristine ^{[1
]}

Bodvarsdottir, Thora B. ^{[2
]}

Karlsen, Allan E. ^{[3
]}

Petersen, Jacob S. ^{[4
]}

Vaag, Allan ^{[1
]}

机构：

[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark

[2] Novo Nordisk, Diabet & Obes Pharmacol, Malov, Denmark

[3] Novo Nordisk, Diabet Biol, Malov, Denmark

[4] Novo Nordisk, Diabet Biol & Pharmacol, Malov, Denmark

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2010年 / 90卷 / 03期

关键词：

Glycaemic control; Type; 2; diabetes; Treatment; Proton pump inhibitors; SERUM GASTRIN; LONG-TERM; NEOGENESIS; THERAPY;

D O I：

10.1016/j.diabres.2010.09.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We retrospectively studied whether treatment with esomeprazole improved HbA(1c) levels in type 2 diabetic patients. We selected 21 patients who had been treated with esomeprazole for 11 +/- 3 months and 21 controls. HbA(1c) levels decreased in the esomeprazole-treated group. Our data indicate that proton pump inhibitors may improve glycaemic control in type 2 diabetic patients. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：E72 / E74

页数：3

共 11 条

[1] Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes [J].